FEDERATED HERMES, INC. - INTELLIA THERAPEUTICS INC ownership

INTELLIA THERAPEUTICS INC's ticker is NTLA and the CUSIP is 45826J105. A total of 279 filers reported holding INTELLIA THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.98 and the average weighting 0.2%.

Quarter-by-quarter ownership
FEDERATED HERMES, INC. ownership history of INTELLIA THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$56,017,296
-32.0%
1,771,578
-12.3%
0.15%
-27.3%
Q2 2023$82,378,822
+9.4%
2,020,0790.0%0.20%
+8.5%
Q1 2023$75,288,344
+2.4%
2,020,079
-4.1%
0.19%
-6.9%
Q4 2022$73,500,844
-13.3%
2,106,645
+39.1%
0.20%
-18.1%
Q3 2022$84,757,000
+15.5%
1,514,600
+6.8%
0.25%
+24.0%
Q2 2022$73,411,000
+63.0%
1,418,300
+128.9%
0.20%
+96.1%
Q1 2022$45,026,000
-30.8%
619,600
+12.6%
0.10%
-15.7%
Q4 2021$65,078,000
-31.4%
550,390
-22.1%
0.12%
-33.1%
Q3 2021$94,821,000
-22.2%
706,830
-6.1%
0.18%
-20.3%
Q2 2021$121,922,000
+129.8%
753,022
+13.9%
0.23%
+120.4%
Q1 2021$53,047,000
+95.3%
660,985
+32.4%
0.10%
+83.9%
Q4 2020$27,165,000
+1051.1%
499,359
+320.6%
0.06%
+833.3%
Q3 2020$2,360,000
+46.9%
118,719
+55.4%
0.01%
+50.0%
Q2 2020$1,606,000
-85.9%
76,391
-88.5%
0.00%
-85.7%
Q1 2019$11,392,000
+25.1%
667,0000.0%0.03%
+12.0%
Q4 2018$9,105,000
-52.3%
667,000
-0.1%
0.02%
-44.4%
Q3 2018$19,105,000
+11.7%
667,525
+6.8%
0.04%
-10.0%
Q2 2018$17,108,000
+35.6%
625,300
+4.5%
0.05%
+35.1%
Q1 2018$12,614,000
+64.1%
598,100
+49.5%
0.04%
+68.2%
Q4 2017$7,688,000400,0000.02%
Other shareholders
INTELLIA THERAPEUTICS INC shareholders Q3 2023
NameSharesValueWeighting ↓
Discovery Value Fund 561,561$17,756,5599.73%
MPM BioImpact LLC 544,639$17,221,4854.60%
Casdin Capital, LLC 1,178,075$37,250,7324.12%
HIMENSION CAPITAL (SINGAPORE) PTE. LTD. 1,145,091$36,207,7773.72%
Atlas Venture Associates IX, LLC 10,000$316,2002.69%
Deep Track Capital, LP 2,000,000$63,240,0002.44%
ARK Investment Management 9,948,629$314,575,6382.41%
Merlin Capital, Inc 18,526$585,7922.19%
Orchard Capital Management, LLC 159,155$5,032,4811.86%
TANG CAPITAL MANAGEMENT LLC 397,600$12,572,1121.77%
View complete list of INTELLIA THERAPEUTICS INC shareholders